Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
HURA
SELLTuHURA Biosciences, Inc. · Healthcare · United States · $134M · Avg Vol: $1M/d
COMPANY DESCRIPTION
TuHURA Biosciences, Inc. is a clinical-stage oncology company developing novel immunotherapies to transform cancer treatment, having recently completed a de-SPAC transaction. The company focuses on leveraging its proprietary technologies to stimulate anti-tumor immune responses. Its innovative approach targets challenging cancers with the potential for improved patient outcomes.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -0.58 | -0.77 | -2.47 | -1.21 | -0.63 | — | -0.61 | -0.50 | -0.56 | — |
| Shares | 42.0M | 42.0M | 42.0M | 42.3M | 59.3M | +41.2% | 63.7M | — | — | — |
| Debt | 0.6M | 0.1M | 2.3M | 0.2M | 0.7M | 2.1% | 0.5M | — | — | — |
| Equity | -0.7M | 12.3M | -1.6M | 14.6M | 20.9M | 19.4% | — | — | — | — |
| Op CF | -6.6M | -7.5M | -12.0M | -14.7M | -27.6M | — | -27.3M | — | — | — |
| Inv CF | -3.3K | -36.3K | -1.3M | -6.1M | -1.3M | — | — | — | — | — |
| Fin CF | 7.0M | 16.3M | 2.7M | 29.8M | 19.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of HURA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| HURA | TuHURA Biosciences, Inc.(you) | $134M | 21 | SELL |
| EQ | Equillium, Inc. | $157M | 23 | SELL |
| ANIX | Anixa Biosciences, Inc. | $126M | 16 | STRONG SELL |
| CDXS | Codexis, Inc. | $135M | 14 | STRONG SELL |
| KPTI | Karyopharm Therapeutics Inc. | $168M | 23 | SELL |
| CNTB | Connect Biopharma Holdings Limited | $135M | 13 | STRONG SELL |
| CNTN | Canton Strategic Holdings, Inc. | $150M | 15 | STRONG SELL |
| ABOS | Acumen Pharmaceuticals, Inc. | $154M | 15 | STRONG SELL |
| ARCT | Arcturus Therapeutics Holdings Inc. | $157M | 15 | STRONG SELL |
| UNCY | Unicycive Therapeutics, Inc. | $148M | 14 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%